Biotech Distilled
| Platform |  | Pricing | Freemium | Publishes | Daily |
|---|---|---|---|---|---|
| Issues | 1116 | Founded | 9 months ago | Last Issue | 3 days ago |
| Active | |||||
Read this Newsletter
biotechdistilled.substack.comLatest Issues
UPDATE: Acumen Pharmaceuticals (ABOS) - The Dilution Gap Re-Opens
This Substack is reader-supported. To receive new posts and support my work, consider becoming a free or paid subscriber.
The Event. Acumen reported Q2 2026 results this morning: $110.2M in cash, cash equivalents and marketable securities...
UPDATE: Adagene (ADAG) - The Answer to the $53M Question
H1 results confirm the cash build was an April equity raise at $3.75/ADS, not a milestone — and the randomized Phase 2 readout that decides this stock just landed on the calendar at 1H 2027.
This Substack is reader-supported. To receive ne...
UPDATE: Allogene Therapeutics (ALLO) - The ATM They Didn’t Use
Zero shares sold under the $135M facility I called a ceiling. Enrollment sites hit the 2026 target six months early. The cap-table objection that drove my June downgrade just failed its first test.
This Substack is reader-supported. To rec...
UPDATE: Altimmune (ALT) - The Q2 Print Quietly Moves a Catalyst
RESTORE’s ALD readout slipped to 2H 2027 on a protocol amendment that shifts the primary endpoint from Week 24 to Week 48 — and $519M in cash says they can afford the wait.
This Substack is reader-supported. To receive new posts and suppor...
UPDATE: Annexon (ANNX) - The Binary Just Grew a Second Half
ARCHER II adds a Month 24 dual primary endpoint alongside Month 15. Management calls it maximizing best-in-class potential; it also means Q4 2026 delivers a committee’s verdict
This Substack is reader-supported. To receive new posts and su...
Key Facts
Audience Metrics
Subscribers, engagement, traffic and sponsorship for Biotech Distilled.
| Subscribers | Engagement | 77 | Monthly Web Visits | ||
|---|---|---|---|---|---|
| Accepts Sponsors | Estimated Cost per Ad | ||||
Chart Rankings
How this newsletter ranks in the official Substack charts.
| #58 |
Authors
The writers behind this newsletter.
PhD in Medicinal Chemistry. Senior Patent Agent. Extensive experience evaluating drug discovery programs — from molecular mechanism to clinical plausibility.
Frequently Asked Questions
How can I access the email archive for Biotech Distilled?
You can find recent issues that have been published by Biotech Distilled on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
How many subscribers does Biotech Distilled have?
To see how many people subscribe to Biotech Distilled, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
How can I advertise in Biotech Distilled?
Newsletter advertising can be extremely effective when it's done right. Before you pitch Biotech Distilled as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
How much does it cost to sponsor a publication like Biotech Distilled?
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact Biotech Distilled using the contact information provided and ask for a copy of their media kit.
How can I find newsletters related to Biotech Distilled?
Scroll up to where it says Related Newsletters to see other publications like Biotech Distilled. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
How do I contact Biotech Distilled?
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.